HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Elicio Therapeutics (NASDAQ:ELTX) but lowered the price target from $11 to $10.

May 01, 2024 | 10:25 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elicio Therapeutics maintains a Buy rating from HC Wainwright & Co., though its price target was reduced from $11 to $10.
The maintenance of a Buy rating suggests a positive outlook on Elicio Therapeutics by HC Wainwright & Co., indicating confidence in the company's fundamentals or future prospects. However, the reduction in the price target could reflect a reassessment of the company's valuation, potential growth, or risks, which might temper short-term investor enthusiasm. The net impact on the stock price could be neutral in the short term as the positive sentiment from maintaining a Buy rating could be offset by the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100